A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride

Trial Profile

A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top